Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | LYN | P07948 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | PRKACA | P17612 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | MARK3 | P27448 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.32 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.32 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.32 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.32 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.32 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.30 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5816913 | 0.73 | AURKA (0.30) | AURKACDK1LYNPIM1FGFR1 | |
| SCHEMBL8689309 | 0.66 | — | — | |
| SCHEMBL17262729 | 0.65 | CDC7 (0.42) | CDK1PRKACARPS6KB1CDK2AKT1 | |
| SCHEMBL17669977 | 0.64 | — | — | |
| SCHEMBL794250 | 0.64 | PARP11 (0.44) | CDK1PIM1RPS6KB1GSK3BMAPK13 | |
| Hydrochloric Acid SCHEMBL4520957 | 0.62 | JAK2 (0.36) | — | |
| SCHEMBL184925 | 0.61 | — | — | |
| SCHEMBL20919789 | 0.59 | CDC7 (0.45) | CDK1PRKACARPS6KB1CDK2AKT1 | |
| SCHEMBL18686362 | 0.59 | — | — | |
| SCHEMBL19339963 | 0.59 | KDM4E (0.42) | CDK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3551632-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2024-06-12 | — | — | EP | disclosed |
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20220362259-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2022-11-17 | — | — | US | disclosed |
| US-11065257-B2 | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2021-07-20 | — | — | US | disclosed |
| EP-3551634-B1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | disclosed |
| US-20200323869-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2020-10-15 | — | — | US | disclosed |
| US-10793580-B2 | Substituted pyrazoloazepin-8-ones and their use as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2020-10-06 | — | — | US | disclosed |
| US-20190330223-A1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2019-10-31 | — | — | US | disclosed |
| EP-3551634-A1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2019-10-16 | — | — | EP | disclosed |
| EP-3551632-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2019-10-16 | — | — | EP | disclosed |
| WO-2018108910-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018108231-A1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-06-21 | — | — | WO | disclosed |
| US-20090054413-A1 | Novel 5,6-Dihydropyrazolo[3,4-E] [L,4]Diazepin-4 (IH) -One Derivatives for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1931672-A1 | NOVEL 5,6-DIHYDROPYRAZOLO[3,4-E] [L,4]DIAZEPIN-4 (IH) -ONE DERIVATIVES FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE. | AstraZeneca AB (SE) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007040435-A1 | NOVEL 5,6-DIHYDROPYRAZOLO[3,4-E] [L,4]DIAZEPIN-4 (IH) -ONE DERIVATIVES FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE. | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054413-A1 | Novel 5,6-Dihydropyrazolo[3,4-E] [L,4]Diazepin-4 (IH) -One Derivatives for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease | PDE4B, PDE4A, PDE12 | AURKA 3354/4885CDK1 1825/4885LYN 4077/4885 |
| US-20190330223-A1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE12, PDE4A, PDE2A | AURKA 2777/4885CDK1 2148/4885LYN 2456/4885 |
| US-20200323869-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE12 | AURKA 2590/4885CDK1 2192/4885LYN 2113/4885 |
| US-20220362259-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE12 | AURKA 2590/4885CDK1 2192/4885LYN 2113/4885 |
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | AURKA 1380/4885CDK1 1237/4885LYN 2732/4885 |
| US-10793580-B2 | Substituted pyrazoloazepin-8-ones and their use as phosphodiesterase inhibitors | PDE12, PDE4A, PDE2A | AURKA 2777/4885CDK1 2148/4885LYN 2456/4885 |
| US-11065257-B2 | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | PDE4A, PDE4B, PDE12 | AURKA 2590/4885CDK1 2192/4885LYN 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.